Human Chorionic Gonadotropin Market Overview
As per MRFR analysis, the Human Chorionic Gonadotropin Market Size was estimated at 1.98 (USD Billion) in 2022. The Human Chorionic Gonadotropin Market Industry is expected to grow from 2.04 (USD Billion) in 2023 to 2.7 (USD Billion) by 2032. The Human Chorionic Gonadotropin Market CAGR (growth rate) is expected to be around 3.17% during the forecast period (2024 - 2032).
Key Human Chorionic Gonadotropin Market Trends Highlighted
The global Human Chorionic Gonadotropin (HCG) market is expanding rapidly due to its extensive usage in fertility treatments, pregnancy diagnosis, and cancer therapy. The increasing prevalence of infertility, advancements in assisted reproductive technologies, and the availability of cost-effective HCG medications drive the market's growth.
Additionally, raising awareness about HCG's potential benefits in cancer treatment, such as testicular and breast cancer, creates new opportunities for market expansion. Key market trends include the development of recombinant HCGs, the emergence of new delivery methods, and the growing adoption of HCG self-testing kits.
These trends are driven by the increasing demand for effective and convenient fertility treatments, early pregnancy detection, and improved cancer outcomes.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Human Chorionic Gonadotropin Market Drivers
Rising Prevalence of Infertility
Infertility is a major global health issue, affecting millions of couples worldwide. The World Health Organization (WHO) estimates that approximately 15% of couples globally struggle with infertility. This number is expected to rise in the coming years due to factors such as delayed childbearing, environmental pollution, and lifestyle changes.
The increasing prevalence of infertility is a key market driver for Human Chorionic Gonadotropin (HCG), as it is a crucial hormone used in fertility treatments such as in vitro fertilization (IVF) and intrauterine insemination (IUI).
HCG triggers ovulation and supports the development of the corpus luteum, which produces progesterone, a hormone essential for maintaining pregnancy. The growing demand for fertility treatments is expected to drive the growth of the Human Chorionic Gonadotropin Market Industry over the forecast period.
Technological Advancements in Fertility Treatments
Advancements in assisted reproductive technologies (ART) have significantly improved the success rates of fertility treatments. The development of new and more effective HCG formulations and delivery systems has played a crucial role in this progress.
For instance, recombinant HCG has a longer half-life than urinary HCG, making it more convenient for patients undergoing fertility treatments. Additionally, the development of devices such as ovulation predictor kits and home-use HCG pregnancy tests has made it easier for individuals to monitor their fertility and detect pregnancy early on.
The ongoing research and development in the field of fertility treatments are expected to further drive the growth of the Human Chorionic Gonadotropin Market Industry.
Increasing Awareness and Accessibility of Fertility Services
The growing awareness about infertility and its treatment options has led to an increased demand for fertility services. Governments and healthcare organizations are implementing various initiatives to improve access to fertility care.
For example, many countries offer financial assistance and insurance coverage for fertility treatments. Additionally, there has been an increase in the number of fertility clinics and specialized healthcare providers offering HCG-based treatments.
The rising awareness and accessibility of fertility services are expected to contribute to the growth of the Human Chorionic Gonadotropin Market Industry in the coming years.
Human Chorionic Gonadotropin Market Segment Insights
Human Chorionic Gonadotropin Market Application Insights
The Global Human Chorionic Gonadotropin (HCG) Market is segmented by application into Infertility Treatment, Ovulation Induction, Pregnancy Testing, and Other Applications. Among these, Infertility Treatment held the largest market share in 2023 and is projected to grow at a CAGR of 3.8% from 2024 to 2032.
The growth of the Infertility Treatment segment can be attributed to the rising prevalence of infertility worldwide and the increasing adoption of assisted reproductive technologies (ART). Ovulation Induction is the second-largest application segment, which accounted for a significant market share in 2023.
It is expected to grow at a CAGR of 3.6% from 2024 to 2032. The growth of the Ovulation Induction segment is driven by the increasing number of women delaying childbearing and the rising demand for fertility treatments.
Pregnancy Testing is another major application segment, which is expected to grow at a CAGR of 3.2% from 2024 to 2032.
The growth of the Pregnancy Testing segment is attributed to the increasing awareness of early pregnancy detection and the availability of affordable and convenient home pregnancy tests. Other Applications of HCG include Luteal Phase Support, Trophoblastic Disease Treatment, and Ectopic Pregnancy Diagnosis.
These applications are expected to contribute to the overall growth of the HCG market over the forecast period.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Human Chorionic Gonadotropin Market Source Insights
The Global Human Chorionic Gonadotropin (HCG) Market is segmented based on source into urine and serum. Urine HCG is derived from the urine of pregnant women, while serum HCG is derived from the blood of pregnant women.
Serum HCG is more commonly used in pregnancy tests and fertility treatments as it is more sensitive and specific than urine HCG. The urine HCG segment is expected to hold a significant market share due to its low cost and easy availability. However, the serum HCG segment is expected to grow at a faster pace due to its increased accuracy and sensitivity.
Human Chorionic Gonadotropin Market Form Insights
The Global Human Chorionic Gonadotropin (HCG) Market is segmented based on form into injectable, oral, and nasal sprays. Among these, the injectable segment accounted for the largest share of the market in 2023, owing to the widespread use of injectable HCG for ovulation induction and assisted reproductive technologies (ART).
The injectable form of HCG is preferred by healthcare professionals due to its ease of administration, precise dosage control, and rapid onset of action. However, the oral and nasal spray segments are gaining traction due to their convenience and non-invasive nature, respectively.
The oral segment is expected to witness significant growth over the forecast period, driven by the increasing adoption of oral HCG for weight loss and body composition management.
Human Chorionic Gonadotropin Market Manufacturing Process Insights
The Global Human Chorionic Gonadotropin (HCG) Market is segmented by manufacturing process into Extraction from Urine and Recombinant DNA Technology. The Extraction from Urine segment accounted for a larger market share in 2023, owing to the established and cost-effective extraction methods used.
However, the Recombinant DNA Technology segment is projected to grow at a faster CAGR from 2024 to 2032, driven by advancements in genetic engineering and increasing demand for high-purity HCG.
The Human Chorionic Gonadotropin Market data shows that the Extraction from Urine segment is expected to reach a valuation of around 0.98 billion USD by 2032, while the Recombinant DNA Technology segment is projected to reach a valuation of approximately 1.72 Billion USD by the same year, indicating a significant market growth potential.
Human Chorionic Gonadotropin Market End User Insights
The end user segment of the Human Chorionic Gonadotropin Market is categorized into hospitals, clinics, diagnostic laboratories, and individuals. Hospitals account for a major share of the market due to the high volume of pregnancy-related tests conducted. In 2023, the hospitals segment generated revenue of approximately USD 0.9 billion and is projected to reach USD 1.2 billion by 2032.
Clinics are another significant end user, contributing to the market growth due to the increasing demand for point-of-care testing. Diagnostic laboratories also play a crucial role in the market, providing specialized testing services for HCG.
The individual segment is expected to witness steady growth over the forecast period as home pregnancy tests become more accessible and affordable.
Human Chorionic Gonadotropin Market Regional Insights
The regional landscape of the Human Chorionic Gonadotropin Market exhibits significant variations in market dynamics and growth opportunities. North America, Europe, APAC, South America, and MEA constitute the key regional segments of the market.
In 2023, North America held the largest market share, driven by factors such as advanced healthcare infrastructure, high prevalence of infertility, and increasing awareness about assisted reproductive technologies. Europe followed closely, with a robust market driven by government initiatives to support fertility treatments and a growing aging population.
APAC is projected to witness the highest growth rate during the forecast period, owing to rising disposable incomes, increasing healthcare expenditure, and expanding access to fertility treatments.
South America and MEA represent emerging markets with growth potential, supported by improving healthcare systems and increasing demand for assisted reproductive services.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Human Chorionic Gonadotropin Market Key Players and Competitive Insights
Major players in the Human Chorionic Gonadotropin Market industry are constantly striving to gain a competitive edge and expand their market share. Leading Human Chorionic Gonadotropin Market players are investing heavily in research and development to introduce innovative products and technologies that cater to the evolving needs of customers.
They are also focusing on strategic partnerships, acquisitions, and mergers to strengthen their position in the market. The Human Chorionic Gonadotropin Market development is driven by factors such as the increasing prevalence of infertility, rising awareness about assisted reproductive technologies, and growing demand for personalized medicine.
Merck, a leading Human Chorionic Gonadotropin Market player, is known for its strong product portfolio and global presence. The company offers a range of Human Chorionic Gonadotropin products, including follitropin alfa and lutropin alfa, which are used in the treatment of infertility. Merck's focus on innovation and customer-centric approach has enabled it to maintain a leading position in the market.
Another prominent player in the Human Chorionic Gonadotropin Market is Ferring Pharmaceuticals. The company has a strong presence in the European market and is expanding its reach into other regions.
Ferring Pharmaceuticals offers a range of Human Chorionic Gonadotropin products, including follitropin beta and urofollitropin, which are used in the treatment of infertility and other reproductive disorders. The company's commitment to research and development has resulted in a robust pipeline of innovative products.
Key Companies in the Human Chorionic Gonadotropin Market Include
- Ferring Pharmaceuticals
- Hetero Labs
- Merck
- LG Chem
- Organon Co.
- Aspen Pharmacare
- Reddy's Laboratories
- Lupin
- intas Pharmaceuticals
- Mylan
- Sun Pharmaceutical Industries
- Pfizer
- Teva Pharmaceutical Industries
- Cipla
- Wuxi Biologics
Human Chorionic Gonadotropin Market Industry Developments
The rising prevalence of infertility and the increasing adoption of assisted reproductive technologies are key factors driving market growth.
Additionally, advancements in HCG production and purification techniques have improved the availability and affordability of HCG products, further contributing to market expansion. Recent news developments include the launch of new HCG formulations, such as long-acting injectables, which offer improved patient convenience and compliance.
The market is also witnessing increased research and development activities focused on developing novel HCG-based therapies for various indications.
Human Chorionic Gonadotropin Market Segmentation Insights
- Human Chorionic Gonadotropin Market Application Outlook
- Infertility Treatment
- Ovulation Induction
- Pregnancy Testing
- Other Applications
- Human Chorionic Gonadotropin Market Source Outlook
- Human Chorionic Gonadotropin Market Form Outlook
- Injectable
- Oral
- Nasal Spray
- Human Chorionic Gonadotropin Market Manufacturing Process Outlook
- Extraction from Urine
- Recombinant DNA Technology
- Human Chorionic Gonadotropin Market End User Outlook
- Hospitals
- Clinics
- Diagnostic Laboratories
- Individuals
| Report Attribute/Metric |
Details |
| Market Size 2022 |
1.98(USD Billion) |
| Market Size 2023 |
2.04(USD Billion) |
| Market Size 2032 |
2.7(USD Billion) |
| Compound Annual Growth Rate (CAGR) |
3.17% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Ferring Pharmaceuticals, Hetero Labs, Merck, LG Chem, Organon Co., Aspen Pharmacare, Dr. Reddy's Laboratories, Lupin, intas Pharmaceuticals, Mylan, Sun Pharmaceutical Industries, Pfizer, Teva Pharmaceutical Industries, Cipla, Wuxi Biologics |
| Segments Covered |
Application, Source, Form, Manufacturing Process, End User, Regional |
| Key Market Opportunities |
Increased fertility treatment Rising demand for assisted reproductive technologies Growing prevalence of infertility Expansion of healthcare infrastructure Advanced research and development initiatives |
| Key Market Dynamics |
Technological advancements Growing demand for fertility treatments Rising incidence of infertility Government initiatives and regulations Increasing healthcare expenditure |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Human Chorionic Gonadotropin Market reached USD 2.04 billion in 2023.
The Human Chorionic Gonadotropin Market is projected to grow at a CAGR of 3.17% from 2024 to 2032.
North America is the largest regional market for Human Chorionic Gonadotropin, accounting for over 40% of the global market share.
The ovulation induction segment is expected to hold the largest market share in the Human Chorionic Gonadotropin Market, owing to the increasing prevalence of infertility worldwide.
Some of the key competitors in the Human Chorionic Gonadotropin Market include Merck Co., Inc., Ferring Pharmaceuticals, and Livzon Pharmaceutical Group Co., Ltd.
The increasing prevalence of infertility, technological advancements in assisted reproductive technologies, and rising awareness about Human Chorionic Gonadotropin are driving the growth of the market.
The high cost of treatment, stringent regulatory approvals, and side effects associated with Human Chorionic Gonadotropin are some of the challenges faced by the market.
The growing demand for assisted reproductive technologies in developing countries, advancements in drug delivery systems, and increasing research and development activities present growth opportunities for the market.
The key trends in the market include the increasing use of recombinant Human Chorionic Gonadotropin, the development of long-acting formulations, and the emergence of personalized medicine approaches.
The Human Chorionic Gonadotropin Market is expected to reach USD 2.7 billion by 2032.
